Mirabegron

Myrbetriq tablets treat adult OAB symptoms of urgency, frequency and urge incontinence, alone or with solifenacin. Pediatric NDO at age ≥ 3: Granules suspension; tablets only when weight ≥ 35 kg. Adult suspension dosage is not established. No pediatric OAB indication is established.

Selected Lupin generic tablets label adult OAB monotherapy and omit protected pediatric-use information; do not assign the branded pediatric indication to that label. Alkem/Ascend generic suspension specifically labels NDO at age ≥ 3, with no recommended adult suspension dose. Current FDA records list selected branded/generic tablets and suspensions Prescription; status does not establish pharmacy stock or an indication beyond the actual PI.

Start 25 mg orally once daily; if needed, increase to 50 mg daily after 4–8 weeks. Branded combination starts mirabegron 25 mg plus solifenacin 5 mg daily; mirabegron may rise to 50 mg after 4–8 weeks. Solifenacin has its own restrictions. Adult tablets may be taken with/without food; swallow whole with water, never divide, chew or crush. No fixed treatment-course duration is specified.

eGFR 30–89 mL/min/1.73 m²: start 25 mg, maximum 50 mg; eGFR 15–29: start/maximum 25 mg. Not recommended below 15 or with dialysis. Child-Pugh A: 25 mg start, 50 mg maximum; B: 25 mg start/maximum; C: not recommended. Adult renal tables use MDRD estimation; assess the correct population/equation.

Age ≥ 3 is required. Below 35 kg, use the verified 8 mg/mL suspension; no labeled band below 11 kg. At ≥ 35 kg, branded tablets start 25 mg daily and may rise to 50 mg after 4–8 weeks; suspension instead starts 6 mL (48 mg) and may rise to 10 mL (80 mg) after 4–8 weeks. Do not combine formulations to reach a total dose. Periodically reassess weight and tolerance; pediatric doses are taken with food.

Use a validated pediatric eGFR equation. With eGFR 15–29 or Child-Pugh B, suspension maximum equals the weight-band starting dose (3, 4 or 6 mL daily); branded tablets at ≥ 35 kg have a 25 mg maximum. With eGFR 30–89 or Child-Pugh A, usual formulation/weight starting and maximum doses apply. Below eGFR 15, dialysis or Child-Pugh C: not recommended. Do not translate the adult tablet ceiling into suspension milligrams.

Pharmacy preparation: keep granules in pouch until reconstitution, discard pouch/desiccant, loosen granules; add 100 mL water, shake 1 minute, stand 10–30 minutes, shake 1 minute again (another minute if not dispersed). Final concentration is 8 mg/mL; date for 28-day discard and supply an appropriate oral device. Before each dose shake vigorously 1 minute, wait for foam to clear about 1–2 minutes, measure and give within 1 hour with food; do not save the dose. If unused for ≥ 2 days, shake for 1 minute each day. This is an approved packaged-product process, not a tablet-compounding recipe.

Take when remembered unless more than 12 hours have passed since the missed dose; then skip and resume the usual schedule. Do not double or combine tablets/suspension. Apply the full-PI missed-dose wording rather than interpreting an ambiguous patient-leaflet phrase as a 12-hour dosing interval.

Known hypersensitivity to mirabegron or inactive ingredients of the exact tablet/suspension. BP, urinary retention and severe organ impairment remain important warnings/restrictions even though not listed as formal contraindications in these selected U.S. labels.

Selected current branded, generic tablet and generic suspension labels have no boxed warning. BP increases, retention, angioedema and interacting-drug exposure remain clinically important.

Adult monotherapy commonly reports hypertension, nasopharyngitis, UTI and headache; combination therapy commonly adds dry mouth/constipation/tachycardia. Pediatric NDO commonly reports UTI, nasopharyngitis, constipation and headache. Postmarketing reports include atrial fibrillation, retention and angioedema; frequency/causality cannot be assigned to every report, including reported neuropsychiatric symptoms. Overdose may raise pulse/BP and cause palpitations; seek urgent poison/emergency assessment with ECG, BP and pulse monitoring.

Mirabegron is a moderate CYP2D6 inhibitor: monitor and consider co-drug adjustment, especially narrow-index substrates such as flecainide, propafenone or thioridazine; metoprolol/desipramine exposure can increase. When starting with digoxin, consider the lowest digoxin dose and monitor serum concentrations for titration. Studied high doses used in interaction experiments are not approved clinical mirabegron regimens.

A single-dose warfarin study did not show INR/PT changes, but repeated-warfarin pharmacodynamic effects are not fully investigated; do not claim an unrestricted absence of interaction. Selected studies do not require routine mirabegron adjustment with ketoconazole, rifampin, tamsulosin or solifenacin, but antimuscarinic co-therapy/outlet obstruction still warrant retention monitoring. Review solifenacin’s independent contraindications and dose limits.

Pediatric NDO evidence covers ages 3–17, with clean intermittent catheterization in the clinical study. Branded tablets require ≥ 35 kg; suspension has separate weight bands. Selected generic tablets omit protected pediatric labeling. No NDO use below 3 or pediatric OAB use is established. Older adult trials found no overall age-related efficacy/safety differences; assess BP, renal function, emptying and medicines individually.

No adequate human pregnancy data define drug-associated risks; animal high exposures caused developmental findings. Human milk, infant effects and milk-production data are unavailable; drug-related material entered rat milk. Consider breastfeeding benefits, maternal clinical need and potential infant harm; do not claim established pregnancy/lactation safety.

Exposure increases in renal/hepatic impairment. Severe renal impairment and Child-Pugh B cap dosing at the appropriate formulation’s starting dose; severe liver disease, eGFR < 15 and dialysis are unstudied/not recommended. Mild/moderate renal and mild hepatic impairment retain usual starting/maximum limits. Pediatric renal assessment needs a validated pediatric equation.

Beta-3 receptor activation relaxes detrusor smooth muscle during bladder storage and increases capacity. Adult tablets peak about 3.5 hours; bioavailability about 29% at 25 mg and 35% at 50 mg, protein binding about 71%, terminal half-life about 50 hours and steady state about 7 days. Metabolism uses multiple pathways; radiolabeled recovery was about 55% urine/34% feces. Exposure is not simply dose-proportional; higher study doses do not define safe prescribing limits.

Suspension pediatric peak about 4–5 hours after a fed single dose, with mean terminal half-life about 26–31 hours. Fasting substantially increases exposure, supporting the pediatric with-food requirement for either appropriate formulation. Tablets and suspension achieve different exposures per milligram. Generic suspension in-vitro alcohol dissolution findings have unestablished clinical impact; no universally validated alcohol-related dose conversion follows.

Follow BP and pulse, urinary urgency/frequency/leakage response, emptying and retention symptoms; reassess organ function and co-medications before escalation. Children need weight/formulation review, food adherence and age/sex/stature BP assessment. Check digoxin levels with combination initiation/titration; review CYP2D6 co-drug effects. ECG/pulse/BP monitoring is indicated in overdose; routine mirabegron serum levels are not prescribed.

Swallow tablets whole; adults may take with/without food but children take their approved formulation with food. Use the measured suspension/device as instructed and follow its 28-day expiry; never substitute milligram for milligram or combine forms. Report rising BP, weak stream/inability to empty and all new medicines. Stop and seek emergency care for face/tongue/throat swelling or breathing difficulty. Follow the > 12-hour missed-dose skip rule.

Myrbetriq 25 mg extended-release tablet: oval brown, Astellas logo and 325; 30-tablet bottle NDC 0469-2601-30. Verify actual packaging/imprint. Product identification does not establish local stock.

Branded and selected generic extended-release tablets: 25/50 mg. Branded Granules and selected generic granules: 830 mg per bottle, reconstituted using 100 mL water to 8 mg/mL suspension. FDA NDA202611, NDA213801, ANDA209485 and ANDA219323 list Prescription products. Pediatric generic suspension labeling is retrieved; selected generic adult tablet labeling omits pediatric information. No injectable mirabegron, immediate-release clinical product or automatic cross-formulation equivalence is inferred.

Tablets/unreconstituted granules: 20–25°C, usual excursions 15–30°C per package. Keep suspension bottle in pouch with desiccant until pharmacy preparation; discard pouch/desiccant at reconstitution. Reconstituted suspension: 20–25°C for up to 28 days, then discard unused medicine. Shake/measure as directed and clean/air-dry the oral device after use. Do not infer refrigerated or home-compounded stability.